HC Wainwright

HC Wainwright initiated coverage of PepGen Inc (NASDAQ: PEPG) with a Buy rating and $26 price target. PepGen is developing next-generation antisense oligonucleotide (ASO) therapeutics for neuromuscular and neurologic diseases. PepGen's lead candidate is PGN-EDO51, a peptide-...

Electric vehicle (EV) equipment provider Blink Charging Co. (NASDAQ: BLNK) reported revenues of $11.5 million, ahead of the consensus estimate of $9.8 million. However, its adjusted loss came in at 41 cents per share, versus Street expectations of a loss of 37 cents a share. Needham On Blink...

InflaRx N.V. (NASDAQ: IFRX) shares are rallying hard Thursday. Here's why.  What Happened: German biopharma InflaRx, which focuses on developing therapies for autoimmune and inflammatory diseases, announced positive data Wednesday from the third cohort of patients in the Phase 2a study...

Plug Power Inc. (NASDAQ: PLUG) announced an acquisition, partnerships, products and updated guidance at its 2021 Plug Symposium. Here's what the Street had to say.  The Plug Power Analysts: RBC Capital Markets analyst Joseph Spak maintained an Outperform rating on Plug Power and...

FibroGen, Inc. (NASDAQ: FGEN) has a key catalyst Thursday when FDA's Cardiovascular and Renal Drugs Advisory Committee will issue its recommendation on the company's new drug application for roxadustat. The committee is scheduled to meet between 9:30 a.m. and 5:30 p.m. Roxadustat was ...

Regeneron Pharmaceuticals Inc.'s (NASDAQ: REGN) robust pipeline and attractive valuation has prompted an analyst at HC Wainwright to join the bullish camp. The Regeneron Analyst: Analyst Michael King initiated coverage of Regeneron shares with a Buy rating and a $703 price target. The...

The advancements with COVID-19 vaccines of Pfizer Inc. (NYSE: PFE), Moderna Inc. (NASDAQ: MRNA), and AstraZeneca Inc. (NASDAQ: AZN), along with a resurgence of stock market indices like the Dow Jones Industrial Average and S&P 500, hints at a relatively stable...

Amarin Corporation plc (NASDAQ: AMRN) shares were tumbling Tuesday in reaction to a negative verdict issued by a U.S. District Court regarding generic versions of its fish oil pill Vascepa. Amarin shares, which rose to 52-week high of $26.12 in mid-December in reaction to a Vascepa...

Nabriva Therapeutics PLC – ADR (NASDAQ: NBRV) shares have gained about 46% year-to-date.  With the average analyst target being $8.42, the shares are primed for further upside provided upcoming catalysts pan out in favor of the company. Benzinga is profiling Nabriva for the benefit...

After initial hiccups such as a tough FDA panel briefing document and a not-so-favorable panel verdict, Karyopharm Therapeutics Inc (NASDAQ: KPTI) managed to secure approval for its multiple myeloma treatment Xpovio three days ahead of the given PDUFA date. The Analyst H.C. Wainwright analyst...

G1 Therapeutics Inc (NASDAQ: GTHX) reported positive top-line results Wednesday for its Phase 2 trilaciclib trial in small cell lung cancer. What Happened The candidate met primary endpoints in reducing the occurrence and duration of severe neutropenia. Compared to the placebo, it also allowed...

Applied Genetic Technologies Corp (NASDAQ: AGTC), a biotech focused on adeno-associated virus-based gene therapies for the treatment of rare diseases, reported disappointing results from an X-linked retinoschisis clinical study. The company also confirmed Biogen Inc (NASDAQ: BIIB) terminated...

Viking Therapeutics Inc (NASDAQ: VKTX), which focuses on therapies for metabolic and endocrine disorders, recently presented Phase 2 data for its non-alcoholic fatty liver disease, or NAFLD, treatment candidate VK2809 at the annual meeting of the American Association for the Study of Liver...

Zynerba Pharmaceuticals Inc (NASDAQ: ZYNE) have dropped by about 12 percent since the company reported third-quarter results Nov. 8. Analysts at HC Wainwright and Canaccord Genuity consider the sell-off an overreaction and issued positive updates on the company this week.  The Analysts HC...

CELYAD SA/ADR (NASDAQ: CYAD) bolstered its entirely bullish cohort of analysts Monday with a fresh buyer. The Rating HC Wainwright analyst Edward White initiated coverage of Celyad with a Buy rating and $45 price target. The Thesis The chimeric antigen receptor therapy, or CAR-T,  ...